MX2024005422A - Dominios de translocacion bacteriana novedosos y polipeptidos recombinantes que los comprenden para su uso en la administracion celular. - Google Patents

Dominios de translocacion bacteriana novedosos y polipeptidos recombinantes que los comprenden para su uso en la administracion celular.

Info

Publication number
MX2024005422A
MX2024005422A MX2024005422A MX2024005422A MX2024005422A MX 2024005422 A MX2024005422 A MX 2024005422A MX 2024005422 A MX2024005422 A MX 2024005422A MX 2024005422 A MX2024005422 A MX 2024005422A MX 2024005422 A MX2024005422 A MX 2024005422A
Authority
MX
Mexico
Prior art keywords
recombinant polypeptides
domains
seq
cellular delivery
translocation domains
Prior art date
Application number
MX2024005422A
Other languages
English (en)
Spanish (es)
Inventor
Roman Melnyk
Greg Beilhartz
Shivneet Gill
Seiji Sugiman-Marangos
Original Assignee
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital For Sick Children filed Critical Hospital For Sick Children
Publication of MX2024005422A publication Critical patent/MX2024005422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1285—Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024005422A 2021-11-04 2022-08-10 Dominios de translocacion bacteriana novedosos y polipeptidos recombinantes que los comprenden para su uso en la administracion celular. MX2024005422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20210100770 2021-11-04
PCT/CA2022/051225 WO2023077210A1 (en) 2021-11-04 2022-08-10 Novel bacterial translocation domains and recombinant polypeptides comprising them for use in cellular delivery

Publications (1)

Publication Number Publication Date
MX2024005422A true MX2024005422A (es) 2024-07-22

Family

ID=86240428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005422A MX2024005422A (es) 2021-11-04 2022-08-10 Dominios de translocacion bacteriana novedosos y polipeptidos recombinantes que los comprenden para su uso en la administracion celular.

Country Status (9)

Country Link
EP (1) EP4426749A1 (https=)
JP (1) JP2024541136A (https=)
KR (1) KR20240099406A (https=)
CN (1) CN118369352A (https=)
AU (1) AU2022381667A1 (https=)
CA (1) CA3237145A1 (https=)
IL (1) IL312574A (https=)
MX (1) MX2024005422A (https=)
WO (1) WO2023077210A1 (https=)

Also Published As

Publication number Publication date
AU2022381667A1 (en) 2024-05-30
KR20240099406A (ko) 2024-06-28
CA3237145A1 (en) 2023-05-11
IL312574A (en) 2024-07-01
EP4426749A1 (en) 2024-09-11
CN118369352A (zh) 2024-07-19
WO2023077210A1 (en) 2023-05-11
JP2024541136A (ja) 2024-11-07

Similar Documents

Publication Publication Date Title
JP6546232B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
MX2023009714A (es) Metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
DE3854842T2 (de) Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
JP2019151638A (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
Ragin et al. Human Müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects
US10457927B2 (en) Multiprotease therapeutics for chronic pain
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
CN104487081A (zh) 用于预防或治疗恶病质的组合物
MX2025009545A (es) Metodos y composiciones para la administracion de sistemas de vector dual otoferlin
US20220193189A1 (en) USE OF Dvl3-DEP PEPTIDE IN PREPARATION OF MEDICAMENT FOR REPAIRING SERTOLI CELL INJURY IN TESTES
Liu et al. Repulsive guidance molecule b inhibits neurite growth and is increased after spinal cord injury
MX2024005422A (es) Dominios de translocacion bacteriana novedosos y polipeptidos recombinantes que los comprenden para su uso en la administracion celular.
Sakumi et al. The Ada protein is a class I transcription factor of Escherichia coli
Wang et al. Internalization of the TAT-PBX1 fusion protein significantly enhances the proliferation of human hair follicle-derived mesenchymal stem cells and delays their senescence
CN114945588A (zh) 抗缪勒氏管激素多肽
Zhang et al. Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in high-fat-diet fed mice
JP6840086B2 (ja) 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント
US20200131495A1 (en) Proteins derived from clpb and uses thereof
Richter et al. High-mobility group protein HMGA2-derived fragments stimulate the proliferation of chondrocytes and adipose tissue-derived stem cells.
JP3647473B2 (ja) 個別性をもつ癌細胞を特徴づけるのに有用な、癌の治療的、予防的、診断的薬剤
US20250041337A1 (en) Fusion protein
BR9506512A (pt) Peptídeo ou conjugado de peptídeo de sequência de aminoácidos composiçao de vacina dna ou rna recombinante plasmídeo plasmídeo pgex célula anti-soro ou anticorpos processos para testar a presença ou quantidade de anticorpos para virus de arterite equina presente em uma amostra e para testar a presença de virus de arterite equina em uma amostra e kit de teste
Park et al. Growth factors improve the proliferation of Jeju black pig muscle cells by regulating MyoD and growth-related genes
MX2025009803A (es) PROTEÍNA DE FUSIÓN QUE COMPRENDE FRAGMENTO DE LA REGIÓN EXTRACELULAR DE TGF-ßRII, COMPOSICIÓN FARMACÉUTICA DE LA MISMA Y USO DE LA MISMA
US10722553B2 (en) Medicament containing recombinant mistletoe lectins for the treatment of brain tumors